Currentblue cross blue shield - tennesseePolicy N/A

Fecal Calprotectin Testing In Adults G2061

Defines coverage criteria and limitations for fecal calprotectin testing in adults (age ≥18) for differential diagnosis between IBD and IBS, monitoring response to therapy, and relapse/monitoring of IBD; excludes other indications. Includes applicable CPT/HCPCS code references and regulatory/FDA device notes.

Policy Summary

Payerblue cross blue shield - tennessee

PolicyFecal Calprotectin Testing In Adults G2061

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionDocument that the patient is ≥18 years old and that the test is being ordered for differential diagnosis of IBD vs IBS, assessment of response to therapy, relapse assessment, or monitoring of IBD, as only these indications meet coverage criteria.

SourceLink

POLICY UPDATE CHANGES

No material changes to clinical coverage criteria or policy content.

3Explicit Coverage Positions

1Procedure Code Listed

6Thresholds/Values Cited

Coverage Summary

Overview: Coverage stance is mixed. Testing is intended for adults aged ≥18. Fecal calprotectin testing is covered when used for: 1) the differential diagnosis between non‑inflammatory gastrointestinal disease (e.g., IBS) and inflammatory gastrointestinal disease (e.g., IBD); 2) assessing response to therapy for IBD; and 3) assessing relapse or monitoring gastrointestinal conditions such as IBD. Assays and numerical cutoffs vary by manufacturer and clinical context; specific thresholds (e.g., 50 µg/g, 150 µg/g, ≤100 µg/g, 139 µg/g, 250 µg) are cited in the Thresholds section.

Key policy facts

Policy titleFecal Calprotectin Testing in Adults

Payer(unspecified in brief metadata) — policy document

Policy numberN/A

Effective date(not provided)

StatusCURRENT

Coverage stanceMixed — meets coverage criteria for adults (≥18) for differential diagnosis of IBD vs IBS, assessing response to therapy, relapse assessment/monitoring; does not meet criteria for other indications

Medical-Necessity Criteria

Medically Necessary / Meets Coverage Criteria

Fecal calprotectin testing MEETS COVERAGE CRITERIA when ALL of the following apply:

ALL of the following

Patient is an adult (18 years of age or older)
One of
- Fecal calprotectin testing for the differential diagnosis between non-inflammatory gastrointestinal disease (e.g., IBS) and inflammatory gastrointestinal disease (e.g., IBD)
- Fecal calprotectin testing to assess for response to therapy for IBD
- Fecal calprotectin testing to assess for relapse or to monitor gastrointestinal conditions such as inflammatory bowel disease (IBD)

ref”: “b1_0”,

title”:

Not Medically Necessary / Does Not Meet Coverage Criteria

Fecal calprotectin testing DOES NOT MEET COVERAGE CRITERIA when ALL of the following apply:

ALL of the following

Patient is an adult (18 years of age or older)
The testing is for any other situations not specifically listed as covered

ref”: “b1_1”,

title”:

Provider Actions

Documentation Required

Confirm patient age and indication

Document that the patient is 18 years of age or older and that the fecal calprotectin test is being ordered for one of the covered indications: differential diagnosis between IBD and IBS, assessment of response to therapy for IBD, relapse assessment, or monitoring of IBD. Only these indications meet coverage criteria for adults.

83993

Billing Rule

Report appropriate procedure code

When submitting claims for fecal calprotectin testing for covered indications, report CPT code 83993 (assay for calprotectin, fecal).

83993

Background & Evidence

Fecal calprotectin is a neutrophil-derived, calcium- and zinc-binding protein that appears in feces when there is intestinal inflammation due to neutrophil migration into the lumen. Detection of fecal calprotectin aids in distinguishing inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) and other noninflammatory causes of gastrointestinal symptoms.

Clinical uses include: differentiating IBD from IBS and other noninflammatory disorders; monitoring disease activity and response to therapy in IBD (including post-induction and treat‑to‑target considerations); and predicting or detecting relapse. Assays may be quantitative or qualitative, use different antibodies or platforms, and show inter-manufacturer variability, so optimal cutoffs depend on clinical context and the specific assay used.

Thresholds / notable values

Common manufacturer cutoff50 µg/g

Suggested young patient cutoff150 µg/g

Normalization for monitoring≤100 µg/g

Predictive cutoff cited139 µg/g

Optimal postop recurrence threshold (meta-analysis)150 µg/g

Alternate positive result definition in study≥250 µg

Evidence / clinical utility

Diagnostic accuracy (meta-analyses)Pooled sensitivity and specificity >90% for distinguishing IBD from IBS at ~50 µg/g (pooled estimates e.g., Waugh et al.: sens 93%, spec 94%)

Predictive value for relapsePooled sensitivity 78% and specificity 73% for predicting relapse in quiescent IBD (Mao et al., 2012)

Monitoring response / clinical utilityNormalization ≤100 µg/g after TNFα induction associated with higher remission; cutoff 139 µg/g predicted active disease at 1 year (sens 72%, spec 80%)

Definitions

IBD: Chronic, immune-mediated inflammatory gastrointestinal disorders (for example, Crohn's disease and ulcerative colitis) characterized by mucosal inflammation and often requiring endoscopic and medical management.

IBS: A noninflammatory functional gastrointestinal disorder marked by abdominal discomfort, bloating, and altered bowel habits; symptoms may overlap with IBD but without objective mucosal inflammation.